Scarring Alopecia: Trichoscopy Signs That Confirm It
How does trichoscopy identify scarring alopecia and why does that finding change management?
The difference between a scalp that can still regrow and one that can't is visible at 20x, and it comes down to what's missing rather than what's there. Once you can read follicular openings reliably, you're not just naming a disease, you're deciding whether your patient's next year gets spent chasing regrowth that will never arrive or protecting the hair they've still got.
- Absent ostia: Smooth ivory or porcelain-white skin with no follicular openings confirms permanent loss.
- Active margin clues: Perifollicular scale and erythema point lymphocytic; pustules and tufts point neutrophilic.
- Bulge destruction: Stem cells sit in the bulge, so a scarred follicle can't cycle again.
- Management pivot: The aim becomes containment, the biopsy goes at the inflamed edge, procedures wait.
Trichoscopy separates scarring from non-scarring hair loss by whether follicular ostia are still present, and once those openings are obliterated the bulge stem cells are gone, so no therapy available today will regrow hair inside that area.
What trichoscopic sign confirms that follicular openings have been permanently destroyed?
The mistake most examiners make is calling a scalp scarred because it looks bare. Bare tells you nothing; the openings do. Work through the stages in order and you'll catch permanent loss months before the scalp looks the part.
A smooth expanse of scalp with no follicular openings in it at all is the confirming sign of permanent destruction, and it should only be called after immersion fluid has cleared the scale and the zone has been re-examined at 50x or higher.
How do perifollicular scale, erythema, and tubular casts point toward lymphocytic scarring alopecia?
Scale on a scalp isn't one finding, it's two very different diseases wearing similar clothes. Seborrhoeic flaking sits between the follicles, greasy and diffuse, while lymphocytic scale wraps the shaft in a tight silvery collar. Get that distinction wrong and you'll treat an advancing scarring alopecia with a medicated shampoo.
- Perifollicular collar: Silvery compact keratin hugging the shaft base, sharply demarcated from the surrounding skin.
- Tubular cast: A movable sleeve that fully encircles the hair and slides millimetres up the shaft.
- Perifollicular erythema: The activity dial; redness around emerging hairs means the disease is burning right now.
- Lonely hair sign: Isolated terminal hairs stranded ahead of a receding frontotemporal band.
Perifollicular scale forming a collar around individual shafts, tubular casts, and perifollicular erythema indicate lymphocytic scarring alopecia such as lichen planopilaris or frontal fibrosing alopecia, but quiet trichoscopy doesn't prove quiet disease, so a scalp with documented follicular loss and no visible inflammation still needs repeat measurement rather than discharge.
Which trichoscopic patterns separate cicatricial alopecia from androgenetic thinning and telogen shedding?
Three conditions, one question, and you can usually settle it in seconds. Look at the openings first, then the shaft calibre, and only then at where the loss sits. Distribution is the least reliable of the three and it's the one most clinicians reach for first.
| Finding | Cicatricial | Androgenetic | Telogen effluvium |
|---|---|---|---|
| Follicular openings | Obliterated | All intact | All intact, many empty |
| Shaft calibre | Scattered solitary hairs | Diversity above 20% men, 10% women | Uniform |
| Scalp surface | Featureless white patch | Peripilar brown halo early | Normal |
| Regrowth picture | None inside the scar | Miniaturised shafts | Short tapered upright hairs |
A featureless white patch with lost follicular openings rules out androgenetic alopecia and telogen effluvium outright, so any island of smooth skin, any perifollicular collar, any tuft, or any itching, burning, or tenderness overrides an otherwise convincing pattern diagnosis.
What features suggest a neutrophilic or mixed scarring process rather than a lymphocytic one?
Neutrophilic disease announces itself loudly, and that's a gift, because the treatment path forks hard here. Antibiotics for a lymphocytic alopecia waste months, and immune suppression on its own won't touch the bacterial driver behind a neutrophilic one. The features that separate them are visible long before histology comes back.
A doll-hair tuft of six or more shafts bursting from a single opening against milky-white fibrosis, alongside follicular pustules and yellow crusting, is close to diagnostic of folliculitis decalvans and redirects treatment toward prolonged antistaphylococcal therapy rather than immune suppression.
When does a trichoscopic finding make a scalp biopsy necessary, and where should the sample be taken?
A punch taken from the middle of an old patch costs your patient a procedure and buys them nothing. The report comes back as dense fibrous tracts, names no disease, and guides no therapy. Where you put that punch matters more than whether you take one at all.
- Confirm the indication: Lost openings with no subtype pattern, clinical and trichoscopic pictures disagreeing, or apparent pattern loss with itching, burning, or tenderness.
- Mark under the scope: Keep the dermatoscope on the scalp while you mark, so the site sits where erythema, scale, or pustules are concentrated.
- Sample the active edge: Take the punch from the inflamed border, never the burnt-out centre.
- Four millimetres, angled, into fat: Follow the direction of hair growth so the whole follicular unit including the bulb comes out.
- Take two: One processed horizontally to count follicles and one vertically for the interface change, adding direct immunofluorescence when lupus is in play.
The biopsy must come from the active inflamed edge that trichoscopy identifies, taken as a four millimetre punch angled along the hair and carried into subcutaneous fat, because a sample from the smooth centre returns only end-stage fibrosis that names no disease and guides no treatment.
Why does destruction of the follicular stem cell region make regrowth in the affected area impossible?
Think of the bulge as the seed stock and the bulb as the crop. You can lose the crop every cycle and rebuild it, which is exactly what a normal follicle does dozens of times over a lifetime. Lose the seed stock and there's nothing left to plant.
- Where the bulge sits: At the arrector pili attachment on the outer root sheath, just below the sebaceous gland.
- Immune privilege: Normally shields the bulge, and cicatricial alopecia is defined by that protection failing.
- Order of destruction: Sebaceous gland goes early, then the bulge, then fibroblasts lay collagen into fibrous tracts.
- Why the drugs can't help: Minoxidil, antiandrogens, and platelet preparations all need a living follicle to act on.
Once the bulge stem cell pool is destroyed there is no source population left to start another anagen phase, so hair inside a scar can't be recovered by minoxidil, antiandrogens, or platelet-derived growth factor preparations, all of which act only on follicles that still exist.
How does a scarring diagnosis shift the treatment goal from regrowth to halting progression?
Success changes definition the moment you confirm a scarring process. A patient whose scalp looks identical in twelve months has had an excellent year, and you'll need to say that out loud early, before they measure your work against the wrong yardstick.
- Start on suspicion: Every month of unchecked inflammation turns living follicles into permanent scar, so don't wait for full certainty.
- Hit the margin first: Potent topical corticosteroid on the active border, often with a topical calcineurin inhibitor so you can rotate off the steroid.
- Inject where it's burning: Intralesional triamcinolone around 2.5 to 10 milligrams per millilitre into the inflamed edge trichoscopy found, every four to six weeks.
- Escalate when it spreads: Hydroxychloroquine, anti-inflammatory dose doxycycline, oral retinoids, mycophenolate, ciclosporin, or a Janus kinase inhibitor in refractory disease.
- Measure stability, not counts: Fixed distance and angle photography, symptom scores, an anagen pull test at the margin, and repeat trichoscopy of a mapped landmark.
In cicatricial alopecia the treatment goal is stability rather than regrowth, so therapy starts on strong clinical suspicion and success is measured by symptom relief, receding erythema and scale, and no measurable extension of the scarred area.
What harm follows from treating an active scarring alopecia as if it were pattern hair loss?
This is the mistake that costs your patient hair they will never get back. It's an easy one to make, because early scarring can look like pattern loss and the wrong treatment even seems to work for a while. Here's what a missed year actually buys them.
Itching, burning, scalp tenderness, a smooth or shiny patch, or loss in a distribution pattern hair loss doesn't produce should trigger a dermatoscopic look at the follicular openings rather than a prescription, and every patient started on pattern-loss therapy needs the scalp examined again at four to six months.
How is trichoscopy used to track disease activity and decide when treatment can be tapered?
Two things are happening on that scalp and they move at completely different speeds. Redness, scale, and casts fade within weeks of effective therapy, while lost openings and white fibrosis never come back. Read them as separate dials and the review visit stops being guesswork.
- Activity dial: Perifollicular erythema, scale, tubular casts, and pustules; reversible and the first to respond.
- Damage dial: Lost openings and white fibrosis; cumulative and permanent, so an enlarging patch means you're not controlled.
- Fixed landmark: A scar, mole, part line, or measured distance from the glabella or tragus, shot at set distance, angle, and magnification.
- Pull test at the border: Several anagen hairs with intact sheaths argues against tapering however calm the surface looks.
Therapy is reduced only after sustained quiet, meaning no symptoms, no perifollicular inflammation, a negative pull test at the margin, and no measurable extension held over a period rather than judged at one calm visit, and it is then stepped down in stages with closer review after each reduction.
How does a scarring diagnosis affect candidacy for hair transplantation or regenerative scalp procedures?
Surgery and stimulation both assume something a scar can't provide: a vascularised bed and an immune environment that will leave the grafts alone. Active cicatricial disease is a firm contraindication, not a caution you weigh against a motivated patient. Where that patient sits on the timeline decides what you can honestly offer them.
Hair transplantation is contraindicated in active cicatricial alopecia and is considered only after prolonged documented quiescence, commonly one to two years with no symptoms, no trichoscopic inflammation, and no measurable extension, and even then graft survival in fibrotic beds runs well below the rates achieved in androgenetic transplantation.
